NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

Conditions

• Colorectal Cancer
• Ovarian Cancer
• Gastric Cancer
• Breast Cancer
• Lung Cancer
• Kidney Cancer
• Melanoma

Interventions

Type	Name	Description
BIOLOGICAL	Autologous or Allogeneic tumor cells	Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.

Timeline

• Start date: 2008-07-01
• Primary completion: 2025-03-01
• Completion: 2027-01-01
• First posted: 2008-07-25
• Last updated: 2025-10-02

Locations

1 site across 1 country: Israel